Latest Trials Latest NewsFAQ

Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Clinical Trials

A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma

Phase 3

Completed

Conditions: Carcinoma, Hepatocellular

Interventions: Drug: Atezolizumab
Drug: Sorafenib
Drug: Bevacizumab

First Posted Date: 2018-02-15

Last Posted Date: 2023-10-23

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 558

Registration Number: NCT03434379

Locations: 🇯🇵
Hokkaido University Hospital, Hokkaido, Japan
🇩🇪
Campus Virchow-Klinikum Charité Centrum 13; Medizinische Klinik; Abt.Hepatologie u.Gastroenterologie, Berlin, Germany
🇨🇦
Jewish General Hospital, Montreal, Quebec, Canada

and more 116 locations

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

Phase 1

Recruiting

Conditions: Metastatic Breast Cancer

Interventions: Drug: Capecitabine
Drug: Atezolizumab
Drug: Ribociclib (dose #1)
Drug: Inavolisib (dose #2)
Drug: Abemaciclib
Drug: Trastuzumab Deruxtecan
Drug: Ipatasertib
Drug: Sacituzumab Govitecan
Drug: Fulvestrant
Drug: Ribociclib (dose #2)
Drug: Inavolisib (dose #1)
Drug: SGN-LIV1A
Drug: Chemotherapy (Gemcitabine + Carboplatin or Eribulin)
Drug: Tocilizumab
Drug: Bevacizumab
Drug: Letrozole
Drug: Nab-Paclitaxel
Drug: Inavolisib
Drug: Selicrelumab

First Posted Date: 2018-02-06

Last Posted Date: 2024-12-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 580

Registration Number: NCT03424005

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
University of California San Diego Medical Center; Moores Cancer Center, La Jolla, California, United States
🇺🇸
Stanford Cancer Institute, Stanford, California, United States

and more 36 locations

A Study to Investigate The Effectiveness Of Atezolizumab In Patients With Inoperable Locally-Advanced Or Metastatic Urothelial Carcinoma Of The Urinary Tract (Announce)

Terminated

Conditions: Urothelial Carcinoma

First Posted Date: 2018-01-16

Last Posted Date: 2019-04-19

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 22

Registration Number: NCT03399643

Locations: 🇩🇪
Urologische Praxis Dr. Krieger, Chemnitz, Germany
🇩🇪
Praxis Dr.med. Wolfgang Hölzer, Berlin, Germany
🇩🇪
Zeisigwaldkliniken Bethanien, Chemnitz, Germany

and more 29 locations

Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors

Phase 2

Terminated

Conditions: Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers

Interventions: Drug: Gemcitabine
Drug: simlukafusp alfa
Drug: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody
Drug: Vinorelbine

First Posted Date: 2017-12-29

Last Posted Date: 2023-02-21

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 256

Registration Number: NCT03386721

Locations: 🇫🇷
ICM; Medecine B3, Montpellier cedex 5, France
🇬🇧
Christie Hospital Nhs Trust; Medical Oncology, Manchester, United Kingdom
🇹🇷
Adana Baskent University Hospital; Medical Oncology, Adana, Turkey

and more 41 locations

A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Emicizumab in Healthy Chinese Volunteers

Phase 1

Completed

Conditions: Hemophilia A
Healthy Volunteers

Interventions: Drug: Emicizumab

First Posted Date: 2017-12-21

Last Posted Date: 2019-09-30

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 16

Registration Number: NCT03380780

Locations: 🇨🇳
Peking University Third Hospital, Beijing, China

Observational Study to Monitor Safety and Effectiveness of Obinutuzumab in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia

Completed

Conditions: Chronic Lymphocytic Leukemia
Follicular Lymphoma

Interventions: Biological: obinutuzumab

First Posted Date: 2017-12-15

Last Posted Date: 2023-01-12

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 55

Registration Number: NCT03374137

Locations: 🇰🇷
Gachon University Gil Medical Center, Incheon, Korea, Republic of
🇰🇷
Pusan National University Hospital, Busan, Korea, Republic of
🇰🇷
Hallym University Sacred Heart Hospital; Department of Hematology, Gyeonggi-do, Korea, Republic of

and more 14 locations

A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer

Phase 3

Completed

Conditions: Triple Negative Breast Neoplasms

Interventions: Drug: Placebo
Drug: Atezolizumab
Drug: Gemcitabine
Drug: Capecitabine
Drug: Carboplatin

First Posted Date: 2017-12-13

Last Posted Date: 2024-11-08

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 595

Registration Number: NCT03371017

Locations: 🇩🇪
Klinikum Essen-Mitte Ev. Huyssens-Stiftung / Knappschafts GmbH; Klinik für Senologie / Brustzentrum, Essen, Germany
🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
🇦🇷
Fundación CENIT para la Investigación en Neurociencias, Buenos Aires, Argentina

and more 133 locations

A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Phase 1

Withdrawn

Conditions: Lymphoma, Non-Hodgkin

Interventions: Drug: Atezolizumab
Drug: Emactuzumab
Drug: Obinutuzumab

First Posted Date: 2017-12-12

Last Posted Date: 2018-04-05

Lead Sponsor: Hoffmann-La Roche

Registration Number: NCT03369964

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States

A Study to Investigate the Bioequivalence or Relative Bioavailability of Three New Idasanutlin Tablet Variants Following Oral Administration in Participants With Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: Idasanutlin

First Posted Date: 2017-12-05

Last Posted Date: 2019-06-19

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 48

Registration Number: NCT03362723

Locations: 🇺🇸
University of Colorado, Aurora, Colorado, United States
🇺🇸
Yale Cancer Center; Medical Oncology, New Haven, Connecticut, United States
🇨🇦
Jewish General Hospital / McGill University, Montreal, Quebec, Canada

and more 8 locations

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139)

Phase 2

Completed

Conditions: Huntington's Disease

Interventions: Drug: RO7234292 (RG6042)

First Posted Date: 2017-11-14

Last Posted Date: 2022-03-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 46

Registration Number: NCT03342053

Locations: 🇬🇧
Central Manchester University Hospitals NHS Foundation Trust; Manchester Centre for Genomic Medicine, Manchester, United Kingdom
🇬🇧
Leonard Wolfson Experimental Neurology Centre, London, United Kingdom
🇩🇪
Universitaetsklinikum Ulm, Ulm, Germany

and more 6 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy